China’s National Medical Products Administration has cleared Neuracle Medical Technology’s implantable brain-computer interface system for commercial sale — the first time any regulator worldwide has granted an invasive BCI full market authorisation rather than a limited research or compassionate-use exemption.
The device is a coin-sized wireless unit that sits on the brain’s outer surface without penetrating cortical tissue. It reads motor-intent signals and translates them into commands that restore hand function in patients with spinal cord injuries. Because the implant rests epidurally rather than threading electrodes into the cortex, Neuracle positions it as a middle path: deeper data access than a scalp-based headset, lower surgical risk than a penetrating array.
From Tsinghua lab to Star Market
Neuracle traces its origins to Tsinghua University’s neuroengineering laboratory. Founded in 2011 by Xu Honglai, who holds a PhD in biomedical engineering from Tsinghua, the company spent more than a decade supplying high-density EEG and evoked-potential systems to research institutions across China — clients include the Chinese Academy of Sciences and Shanghai Jiao Tong University — before pivoting toward therapeutic implants.
The company moved through NMPA’s “innovative green channel,” a fast-track pathway Beijing created specifically for breakthrough medical devices. That regulatory infrastructure has become a competitive weapon: while Neuralink still operates under an FDA investigational device exemption limited to a small number of patients in the United States, Neuracle can now sell its system to any qualified Chinese hospital.
Last month Neuracle signed an IPO tutoring agreement with Citic Securities, beginning the listing process on the Shanghai Stock Exchange’s Star Market. The NMPA clearance materially strengthens that prospectus.
Market reaction and competitive landscape
Shenzhen-listed Inkon Life Technology, which supplies BCI-adjacent components, surged more than ten per cent on the news. The reaction signals how seriously Chinese public markets are treating the sector since Beijing outlined a target of developing two or three globally competitive BCI companies by 2030, with core technology breakthroughs expected by 2027.
Neuracle is not the only Chinese firm moving fast. StairMed Technology, which pursues a penetrating-electrode approach more analogous to Neuralink’s, just closed a 500 million yuan round led by Alibaba. NeuroXess broke ground on what it calls China’s first BCI production facility earlier this month. And Gestala, backed by Shanda Interactive founder Tianqiao Chen, recently raised 150 million yuan for an ultrasound-based alternative.
The NMPA decision does not automatically translate to large-scale adoption — reimbursement pathways, surgeon training pipelines, and long-term safety data will all gate diffusion. But it removes the single largest regulatory barrier and gives Neuracle a first-mover advantage no Western competitor currently holds.